Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 26, No 15S (May 20 Supplement), 2008: 9004
© 2008 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Eggermont, A. M. Search for Related Content PubMed Articles by Eggermont, A. M.

Abstract

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

Erasmus University Medical Center, Rotterdam, The Netherlands; European Organisation for Research and Treatment of Cancer, Brussels, Belgium; M. S-K Memorial Cancer Center, Warsaw, Poland; Birmingham University, Birmingham, United Kingdom; European Institute of Oncology, Milan, Italy; Oncology Centre Addenbrooke’s Hospital, Cambridge, United Kingdom; Norwegian Radium Hospital, Oslo, Norway; Pascale National Cancer Institute, Napels, Italy; St. James’s Hospital, Leeds, United Kingdom; Institut Gustave-Roussy, Villejuif, France

9004

Background: EORTC 18961 assessed in the largest adjuvant phase III trial to date in stage II melanoma the efficacy and toxicity of Ganglioside GM2-KLH21 Vaccination (VAC) Treatment vs Observation (OBS). Methods: Patients (Pts) were observed or received vaccine sc once weekly week 1–4, every 3 months from week 12 for first 2 years and every 6 months during third year (total of 14 vaccinations). Stratification factors for randomization were: Breslow thickness, ulceration, being staged yes vs no by Sentinel Node (SNLD) or Elective Lymph Node Dissection (ELND), sex and institution. Relapse-free survival (RFS) was the primary endpoint; Distant metastasis-free survival (DMFS) and overall survival (OS) were the prespecified secondary endpoints. Intent-to-treat analysis was performed. Results: Between March 2002 and Dec. 2005, 1,314 pts entered the trial. Patient demographics showed perfect balance for prognostic factors. The 2nd interim analysis was performed when 267 RFS events were reported, i.e. 67% of the total number required at final analysis. Median follow-up was 1.8 years. Similar treatment differences were obtained in lympnhnode-staged (N=644) or non-staged (N=670) patients. Grade 3 - toxicities occurred in < 2%.(VAC) and in < 1% (OBS). Grade 2 - toxicities comprised fatigue (15% vs 3%), fever (9% vs 1%), nausea (3% vs 1%). Local grade 3 - toxicity occurred in 4 % (VAC). The EORTC IDMC reviewed both safety and efficacy data. For the primary endpoint, RFS, the criteria for stopping for futility were met. For DMFS and OS, the results pointed in the direction of a detrimental effect of the vaccine. The IDMC recommended trial 18961 to be stopped and vaccinations to be halted in pts still receiving VAC. Pts should continue to be followed for the trial’s endpoints. Conclusions: Adjuvant GM2-KLH21 vaccination is ineffective and could even be detrimental in stage II melanoma patients.

Abstract presentation from the 2008 ASCO Annual Meeting